. FACS analysis and relative quantification of HSCs (CD117 + , Sca1 + gated on Lin -), Ter119 gated on CD45 -cells, lymphoid precursors (SCA1 + gated on CD117 + , CD127 + , Lin -), NK precursors (NK1.1 -gated on CD122 + , Lin -), pre-granulocytes (CD127 -, CD16/32 + gated on CD117 + , SCA1 -, CD34 + , Lin -) and myeloid (SCA1gated on CD117 -, CD127 + , Lin -) in (a) bone marrow isolated from Vehicle-and SR59230A-treated mice and in (b) untreated-tumor mass disrupted and cultured ex-vivo and then treated with Vehicle and SR59230A. Cells were then analyzed after 7 days of treatments.
. (a) Blood analysis and (b) mice weight measurement after 20 days of treatment. Table S1 . Fluorochrome-conjugated antibodies dilutions used in FACS analysis.
Antibody
Dilution Anti-CD45-VioBlue (130-110-802) 1:50 Anti-CD45-VioGreen (130-102-776) 1:50 Anti-CD11b-FITC or PerCPVio700 (130-109-289) 1:50 Anti-Gr1-PE (130-102-426) 1:10 Anti-CD106-PE (130-104-712) 1:10 Anti-SCA-1-PE or Vio700 (130-106-220) 1:10 Anti-CD73-FITC (130- 
